Nurix Therapeutics Extends Collaboration with Gilead Sciences
Nurix Therapeutics announces extension of research collaboration with Gilead Sciences
Overview
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced that Gilead Sciences has elected to extend the research term of the companies’ ongoing collaboration, originally established in 2019, by an additional two years.
CSO Nurix on Extention
- Gilead’s extension of the research period of this agreement is a testament to the productivity of our collaboration to date. Most importantly, it increases the opportunity for additional clinical candidates and associated milestones to emerge from our work together with the Gilead team,” said Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix.
- Progress in the collaboration has already yielded the first development candidate GS-6791 (NX-0479), a potent, selective, oral IRAK4 degrader that has potential applications in the treatment of rheumatoid arthritis and other inflammatory diseases, which Gilead licensed in March 2023. With this extended research term, we aim to deliver multiple additional clinical candidates to advance a portfolio of novel targeted protein degrader therapies with Gilead.”
Terms of Agreement
- Under the collaboration agreement, Nurix is deploying its proprietary drug discovery platform to identify novel agents that use E3 ligases to induce degradation of specified drug targets.
- Gilead has an option to license drug candidates resulting from the work, and Nurix retains co-development and co-detail options on up to two programs in the United States, subject to certain restrictions.
- For those programmes that Nurix opts in to co-develop and co-detail, the parties will split development costs as well as profits and losses 50/50 for the United States, and Nurix will be eligible to receive royalties on ex-US sales and reduced milestone payments.
- Upon signing the agreement in 2019, Gilead made an upfront payment of $45.0 million. Through Nurix’s fiscal year-end of November 30, 2023, Nurix has received an additional $70.0 million including research milestones, the IRAK4 degrader license option exercise payment and additional payments.
- In connection with today's announcement, Nurix will receive a $15.0 million extension fee and remains eligible for up to $73.5 million in preclinical milestones and potential future licensing payments and up to a total of $1.7 billion in potential future development, regulatory, and sales milestones as well as royalties on future products.
Nurix Therapeutics
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
